CA9 and renal cell carcinoma: There are currently several ongoing studies of CAR-T cell therapy in mRCC against different targets, including CAIX (NCT04969354), CD70 (COBALT-RCC, NCT04438083), and AXL/ROR2 (NCT03393936).